Voya Investment Management LLC Grows Position in Sanofi $SNY

Key Points

• Voya Investment Management LLC increased its stake in Sanofi by 11.6%, now owning 206,635 shares valued at approximately $11.46 million.
• Several hedge funds also boosted their investments in Sanofi, with Brighton Jones LLC dramatically increasing its stake by 52.6% in the fourth quarter.
• Sanofi reported an earnings per share (EPS) of $0.90 for the last quarter, missing analysts' expectations of $0.96 while generating $11.34 billion in revenue.

Voya Investment Management LLC raised its stake in Sanofi (NASDAQ:SNY - Free Report) by 11.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 206,635 shares of the company's stock after purchasing an additional 21,540 shares during the period. Voya Investment Management LLC's holdings in Sanofi were worth $11,460,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in SNY. Nuveen LLC purchased a new position in Sanofi in the first quarter valued at about $177,831,000. Federated Hermes Inc. grew its stake in Sanofi by 58.5% in the first quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company's stock valued at $218,933,000 after purchasing an additional 1,456,269 shares during the last quarter. OLD Mission Capital LLC purchased a new position in Sanofi in the first quarter valued at about $48,938,000. Raymond James Financial Inc. grew its stake in Sanofi by 15.1% in the first quarter. Raymond James Financial Inc. now owns 3,244,027 shares of the company's stock valued at $179,914,000 after purchasing an additional 425,597 shares during the last quarter. Finally, GAMMA Investing LLC grew its stake in Sanofi by 8,703.0% in the first quarter. GAMMA Investing LLC now owns 335,921 shares of the company's stock valued at $18,630,000 after purchasing an additional 332,105 shares during the last quarter. Hedge funds and other institutional investors own 14.04% of the company's stock.

Sanofi Price Performance

Shares of SNY stock traded down $0.04 during trading hours on Friday, hitting $47.64. 4,317,340 shares of the company's stock were exchanged, compared to its average volume of 2,720,287. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The firm has a market cap of $116.98 billion, a P/E ratio of 11.45, a P/E/G ratio of 1.12 and a beta of 0.51. The firm has a 50 day moving average of $48.49 and a two-hundred day moving average of $50.87. Sanofi has a fifty-two week low of $44.73 and a fifty-two week high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The business had revenue of $11.34 billion for the quarter, compared to analyst estimates of $9.91 billion. During the same period in the previous year, the company earned $1.73 earnings per share. The company's quarterly revenue was down 7.0% compared to the same quarter last year. Sell-side analysts forecast that Sanofi will post 4.36 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on SNY. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "hold" rating to a "buy" rating in a research note on Tuesday, September 2nd. Morgan Stanley upgraded shares of Sanofi from an "equal weight" rating to an "overweight" rating and upped their price objective for the company from $56.00 to $58.00 in a report on Monday, September 8th. Wall Street Zen upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. JPMorgan Chase & Co. upgraded shares of Sanofi from a "neutral" rating to an "overweight" rating in a report on Friday, August 8th. Finally, Barclays restated an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $62.67.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.